Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHAT | P28329 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315078 | 0.78 | HTR2A (0.41) | HTR2AALDH1A1TSHRMAOBCYP2A6 | |
| SCHEMBL28039489 | 0.78 | TSHR (0.41) | ALDH1A1TSHRMAOBCYP2A6LMNA | |
| SCHEMBL10822902 | 0.77 | CYP2A6 (0.44) | MAOBCYP2A6L3MBTL1RELA | |
| SCHEMBL27437505 | 0.77 | CYP3A4 (0.38) | HTR2AALDH1A1TSHRAHRLMNA | |
| SCHEMBL27633315 | 0.76 | HTR2A (0.40) | HTR2AALDH1A1TSHRMAOBCYP2A6 | |
| SCHEMBL5165697 | 0.75 | MAOB (0.46) | HTR2AMAOBAHRLMNACHAT | |
| SCHEMBL10574618 | 0.75 | MAOB (0.46) | HTR2AMAOBAHRLMNACHAT | |
| SCHEMBL3335734 | 0.75 | CHRM5 (0.50) | MAOBCHATRELA | |
| SCHEMBL7572963 | 0.74 | HTR2A (0.48) | HTR2AALDH1A1CYP2A6LMNA | |
| SCHEMBL8704500 | 0.74 | HTR2A (0.39) | HTR2AALDH1A1TSHRMAOBCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1871741-A2 | SUBSTITUTED AZETIDINONES | Daiamed, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | HTR2A 334/4885ALDH1A1 2503/4885TSHR 414/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | HTR2A 334/4885ALDH1A1 2503/4885TSHR 414/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | HTR2A 334/4885ALDH1A1 2503/4885TSHR 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.